Key result
IVIG and tirofiban discontinuation normalize platelets within 3 days in severe drug-induced thrombocytopenia.
Why the study?
Glycoprotein IIb/IIIa inhibitors such as tirofiban are used during primary PCI for ACS with high thrombus burden, but they can occasionally cause severe, potentially life-threatening immune-mediated thrombocytopenia if not promptly recognized.
Does immediate discontinuation of tirofiban and dual antiplatelet therapy combined with intravenous immunoglobulin (IVIG) administration reverse severe tirofiban-induced thrombocytopenia in a patient undergoing primary PCI for anterior STEMI?
Case Report (n=1)
No
Does immediate discontinuation of tirofiban and dual antiplatelet therapy combined with intravenous immunoglobulin (IVIG) administration reverse severe tirofiban-induced thrombocytopenia in a patient undergoing primary PCI for anterior STEMI?
Early recognition of severe tirofiban-induced thrombocytopenia after primary PCI, immediate cessation of tirofiban and antiplatelets, and administration of IVIG enabled rapid platelet recovery within 72 hours and safe resumption of antithrombotic therapy for a concurrent left ventricular thrombus.
Answers are grounded in this paper and cite their sources.
Supports IVIG after tirofiban cessation for rapid recovery; leaves open need for prospective data on management.
Background: Glycoprotein IIb/IIIa inhibitors such as tirofiban are potent intravenous antiplatelet agents used in acute coronary syndromes (ACS), particularly in patients with high thrombus burden undergoing primary percutaneous coronary intervention (PCI). Although highly effective, they can occasionally cause severe, immune-mediated thrombocytopenia, which may be life-threatening if not promptly recognized. Case Presentation: A 43-year-old male with anterior wall ST-elevation myocardial infarction (STEMI) underwent successful primary PCI with thrombus aspiration and drug-eluting stent implantation in the left anterior descending artery. Due to a large thrombus burden, tirofiban was administered as a bolus followed by continuous infusion. Within nine hours, the platelet count dropped from 211 × 10⁹/L to 6 × 10⁹/L, accompanied by ecchymoses but no active bleeding. Comprehensive evaluation excluded heparin-induced thrombocytopenia, disseminated intravascular coagulation, and infection-related causes. A diagnosis of tirofiban-induced thrombocytopenia was established by exclusion. Immediate discontinuation of tirofiban and antiplatelet therapy, followed by intravenous immunoglobulin (IVIG) administration, resulted in a rapid platelet recovery to 43 × 10⁹/L within 24 hours and normalization within three days. The patient was subsequently restarted on clopidogrel monotherapy and rivaroxaban for management of a left ventricular thrombus. Conclusion: This case underscores the importance of early recognition, prompt discontinuation of tirofiban, and multidisciplinary management in treating severe tirofiban-induced thrombocytopenia. Timely intervention and the use of IVIG can be lifesaving and prevent catastrophic bleeding or thrombotic complications.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (2026) conducted a case report in Tirofiban-induced severe thrombocytopenia following primary percutaneous coronary intervention for anterior wall ST-elevation myocardial infarction (n=1). Tirofiban discontinuation and Intravenous Immunoglobulin (IVIG) was evaluated on Platelet count recovery. Tirofiban discontinuation and IVIG therapy restored platelet counts from 6 × 10⁹/L to 43 × 10⁹/L within 24 hours and 214 × 10⁹/L within 3 days in severe tirofiban-induced thrombocytopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: